ILUVIEN eye implant for kids with recurrent eye inflammation
Part of Eyes & vision clinical trials.
This trial tests an eye implant (ILUVIEN) in children and teens ages 6 to 17 who have a type of eye inflammation called uveitis that keeps coming back. The implant releases medicine slowly over time to control inflammation and may help reduce the need for other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old.
- You have eye inflammation (uveitis) in the back part of one or both eyes that comes back at least once a year.
- Current treatments for this eye inflammation haven't worked well or have caused bad side effects.
- You have taken steroid pills or other body-wide treatments for at least 3 months in the past year.
- You have not had eye surgery in the study eye in the last 90 days.
- You do not have glaucoma or high eye pressure that is not well controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how often and how severely inflammation returns (relapses) in people who have a steroid implant in the eye for non-infectious uveitis. It may help doctors understand the long-term effects of this treatment.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
This trial tests a new drug called FXS5626 to treat non-infectious uveitis—inflammation inside the eye that doesn't come from infection. The study looks at whether this drug can reduce eye inflammation and improve vision in people whose condition isn't controlled with steroid eye drops and oral steroids alone.
This trial tests a new eye drop (tacrolimus) to treat non-infectious anterior uveitis, an inflammation in the front part of the eye. It may help reduce the need for steroid eye drops.
This study follows people with non-infectious uveitis (inflammation inside the eye) that affects the middle or back of the eye. It aims to understand the disease better and see how different treatments work, which may help improve future care.
This trial tests a new drug called tulisokibart for people with active inflammation in the back of the eye (uveitis). The drug may help reduce inflammation and prevent vision loss.
Hear when a new Non-infectious Uveitis Affecting the Posterior Segment of the Eye trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.